129 related articles for article (PubMed ID: 31826481)
1. A fucoidan-quaternary chitosan nanoparticle adjuvant for anthrax vaccine as an alternative to CpG oligodeoxynucleotides.
Chuang CC; Tsai MH; Yen HJ; Shyu HF; Cheng KM; Chen XA; Chen CC; Young JJ; Kau JH
Carbohydr Polym; 2020 Feb; 229():115403. PubMed ID: 31826481
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles assembled from fucoidan and trimethylchitosan as anthrax vaccine adjuvant: In vitro and in vivo efficacy in comparison to CpG.
Tsai MH; Chuang CC; Chen CC; Yen HJ; Cheng KM; Chen XA; Shyu HF; Lee CY; Young JJ; Kau JH
Carbohydr Polym; 2020 May; 236():116041. PubMed ID: 32172855
[TBL] [Abstract][Full Text] [Related]
3. Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909).
Minang JT; Inglefield JR; Harris AM; Lathey JL; Alleva DG; Sweeney DL; Hopkins RJ; Lacy MJ; Bernton EW
Vaccine; 2014 Nov; 32(50):6847-54. PubMed ID: 24530403
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
Bento D; Staats HF; Gonçalves T; Borges O
Eur J Pharm Biopharm; 2015 Jun; 93():149-64. PubMed ID: 25818119
[TBL] [Abstract][Full Text] [Related]
5. CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine.
Klinman DM
Expert Rev Vaccines; 2006 Jun; 5(3):365-9. PubMed ID: 16827620
[TBL] [Abstract][Full Text] [Related]
6. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.
Xie H; Gursel I; Ivins BE; Singh M; O'Hagan DT; Ulmer JB; Klinman DM
Infect Immun; 2005 Feb; 73(2):828-33. PubMed ID: 15664922
[TBL] [Abstract][Full Text] [Related]
7. Effect of CpG oligonucleotides on vaccine-induced B cell memory.
Tross D; Klinman DM
J Immunol; 2008 Oct; 181(8):5785-90. PubMed ID: 18832738
[TBL] [Abstract][Full Text] [Related]
8. A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.
Kachura MA; Hickle C; Kell SA; Sathe A; Calacsan C; Kiwan R; Hall B; Milley R; Ott G; Coffman RL; Kanzler H; Campbell JD
J Immunol; 2016 Jan; 196(1):284-97. PubMed ID: 26608924
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Immunostimulatory Effects of N-(2-Hydroxy) Propyl-3-Trimethylammonium Chitosan Chloride for Improving Live Attenuated Hepatitis A Virus Vaccine Efficacy.
Tao W; Fu T; He Z; Hu R; Jia L; Hong Y
Viral Immunol; 2017 Mar; 30(2):120-126. PubMed ID: 27918250
[TBL] [Abstract][Full Text] [Related]
10. N-(2-hydroxy) propyl-3-trimethylammonium chitosan chloride: An immune-enhancing adjuvant for hepatitis E virus recombinant polypeptide vaccine in mice.
Tao W; Zheng HQ; Fu T; He ZJ; Hong Y
Hum Vaccin Immunother; 2017 Aug; 13(8):1818-1822. PubMed ID: 28604244
[TBL] [Abstract][Full Text] [Related]
11. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
[TBL] [Abstract][Full Text] [Related]
12. Novel protein-loaded chondroitin sulfate-N-[(2-hydroxy-3-trimethylammonium)propyl]chitosan nanoparticles with reverse zeta potential: preparation, characterization, and ex vivo assessment.
Tsai TN; Yen HJ; Chen CC; Chen YC; Young YA; Cheng KM; Young JJ; Hong PD
J Mater Chem B; 2015 Nov; 3(44):8729-8737. PubMed ID: 32262730
[TBL] [Abstract][Full Text] [Related]
13. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine.
Klinman DM; Xie H; Ivins BE
Ann N Y Acad Sci; 2006 Oct; 1082():137-50. PubMed ID: 17145935
[TBL] [Abstract][Full Text] [Related]
14. Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants.
Klinman DM; Klaschik S; Tomaru K; Shirota H; Tross D; Ikeuchi H
Vaccine; 2010 Feb; 28(8):1919-23. PubMed ID: 20188247
[TBL] [Abstract][Full Text] [Related]
15. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
[TBL] [Abstract][Full Text] [Related]
16. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.
Sloat BR; Cui Z
Pharm Res; 2006 Jun; 23(6):1217-26. PubMed ID: 16718616
[TBL] [Abstract][Full Text] [Related]
17. Comparisons of the humoral and cellular immunity induced by live A16R attenuated spore and AVA-like anthrax vaccine in mice.
Lv J; Zhang YY; Lu X; Zhang H; Wei L; Gao J; Hu B; Hu WW; Hu DZ; Jia N; Feng X
Biologicals; 2017 Mar; 46():130-138. PubMed ID: 28215694
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous formulation of influenza vaccine and chitosan nanoparticles within CpG oligodesoxi nucleotides leads to dose-sparing and protects against lethal challenge in the mouse model.
Sadati SF; Jamali A; Abdoli A; Abedi-Valugerdi M; Gholami S; Alipour S; Soleymani S; Kheiri MT; Atyabi F
Pathog Dis; 2018 Nov; 76(8):. PubMed ID: 30184220
[TBL] [Abstract][Full Text] [Related]
19. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery.
Sayin B; Somavarapu S; Li XW; Thanou M; Sesardic D; Alpar HO; Senel S
Int J Pharm; 2008 Nov; 363(1-2):139-48. PubMed ID: 18662762
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic study of the adjuvant effect of chitosan-aluminum nanoparticles.
Lebre F; Pedroso de Lima MC; Lavelle EC; Borges O
Int J Pharm; 2018 Dec; 552(1-2):7-15. PubMed ID: 30244149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
